News – Page 22 – Pharma Strategies | Zimbabwe, Zambia, South Africa

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
arcticnovartis
Mon, 02/05/2024 – 22:48

Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients¹

Print
PDF

February 5, 2024/by arcticnovartis

Novartis News

Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen

Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
arcticnovartis
Wed, 01/31/2024 – 07:02

Ad-hoc-Mitteilung gemäss Art. 53 KR

Geschäftsjahr (fortzuführende Geschäftsbereiche²)

Print
PDF

January 31, 2024/by arcticnovartis

Novartis News

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
arcticnovartis
Wed, 01/31/2024 – 07:02

Annonce événementielle au sens de l’art. 53 RC

Exercice complet (activités poursuivies²)

Print
PDF

January 31, 2024/by arcticnovartis

Novartis News

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
arcticnovartis
Wed, 01/31/2024 – 07:02

Ad hoc announcement pursuant to Art. 53 LR

Full year (continuing operations²)